HTS and Proteomics

HTS 和蛋白质组学

• 批准号: 8011760
• 负责人: Julian P Whitelegge
• 金额: $ 39.7万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-05 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8011760
• 关键词: Arts; Biological; Cells; Chemical Structure; Chemicals; Data; Databases; Family; Funding; Housing; Lead; Mass Spectrum Analysis; Measures; Mining; Molecular Profiling; Pathway interactions; Pharmaceutical Preparations; Pharmacologic Substance; Pilot Projects; Play; Proteomics; Radiation; Research; Research Project Grants; Role; Services; Structure-Activity Relationship; Technology; Work; analog; chemical synthesis; cheminformatics; data mining; design; driving force; drug discovery; high throughput screening; improved; novel; pharmacophore; response; small molecule libraries

Core D is critical for the central tenet ofthe UCLA-CMCR, which is that classes of mitigators of radiation damage can be identified by their chemical structures and/or the biological pathways that they utilize. Core D has provided and will continue to provide the technological driving force behind the work ofthe projects in high-throughput screening (HTS) of small molecule libraries with the aim of discovering novel mitigators of radiation damage. Core D centralizes HTS in a state-of-the-art facility that has already proven its value to the UCLA-CMCR, with several families of lead compounds identified. Additionally, in order to deal with the data that has been generated and to provide it to the CMCR in a form in which it can be mined for structureactivity relationships and other relevant chemical and biological information Core D, through pilot research funding, has established a relationship with Collaborative Drug Discovery (CDD) to use its an industrialstrength database for these purposes. Access to this data is available to other CMCRs. Now that families of lead compounds have been identified, with more to come. Core D has been further expanded to include pharmaceutical chemists under Dr. Jung, who will play a central role in design and synthesis of analogues of active compounds to identify chemical structures responsible for activity, to improve their drug-like qualities, and their efficacy. This relationship also was initiated through pilot research funding. Finally, Core D provides proteomics primarily in the form of mass spectrometry to seek molecular signatures ofthe biological pathways utilized by effective mitigators so as to probe mechanism of action of these compounds.

核心D对于UCLA-CMCR的中心宗旨至关重要，即辐射的缓解剂类别 损害可以通过其化学结构和/或它们使用的生物途径来识别。核心d 已经提供并将继续提供项目工作背后的技术推动力 小分子库的高通量筛选（HTS），目的是发现新颖的缓解剂 辐射损坏。核心D将HT集中在最先进的设施中，该设施已经证明了其价值 UCLA-CMCR，确定了几种铅化合物家族。此外，为了处理数据 已经生成并将其提供给CMCR的形式，可以将其开采以进行结构反应性 通过试点研究，关系以及其他相关的化学和生物信息核心D 资金，已经与协作药物发现（CDD）建立了关系，以使用其工业发展 数据库出于这些目的。其他CMCR可以访问此数据。现在 铅化合物已被鉴定出来，还有更多。核心D已进一步扩展到包括 荣格博士的药物化学家将在设计和合成的类似物中发挥核心作用 活性化合物以识别负责活性的化学结构，以提高其类似药物的品质， 和他们的功效。这种关系也通过试点研究资金启动。最后，核心d 提供蛋白质组学主要以质谱法的形式，以寻求生物学的分子特征 有效缓解剂利用的途径以探测这些化合物的作用机理。